- Home
- YCBD vs BTAI Comparison
YCBD vs BTAI Comparison
Compare YCBD & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YCBD
- BTAI
- Stock Information
- Founded
- YCBD 2015
- BTAI 2017
- Country
- YCBD United States
- BTAI United States
- Employees
- YCBD N/A
- BTAI N/A
- Industry
- YCBD Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- YCBD Health Care
- BTAI Health Care
- Exchange
- YCBD Nasdaq
- BTAI Nasdaq
- Market Cap
- YCBD 7.8M
- BTAI 8.3M
- IPO Year
- YCBD N/A
- BTAI 2018
- Fundamental
- Price
- YCBD $0.95
- BTAI $1.81
- Analyst Decision
- YCBD Strong Buy
- BTAI Buy
- Analyst Count
- YCBD 1
- BTAI 5
- Target Price
- YCBD $3.00
- BTAI $34.80
- AVG Volume (30 Days)
- YCBD 67.8K
- BTAI 325.6K
- Earning Date
- YCBD 08-13-2025
- BTAI 08-05-2025
- Dividend Yield
- YCBD N/A
- BTAI N/A
- EPS Growth
- YCBD N/A
- BTAI N/A
- EPS
- YCBD N/A
- BTAI N/A
- Revenue
- YCBD $19,593,146.00
- BTAI $1,852,000.00
- Revenue This Year
- YCBD $13.00
- BTAI N/A
- Revenue Next Year
- YCBD $10.00
- BTAI $362.49
- P/E Ratio
- YCBD N/A
- BTAI N/A
- Revenue Growth
- YCBD N/A
- BTAI 5.47
- 52 Week Low
- YCBD $0.76
- BTAI $1.17
- 52 Week High
- YCBD $6.54
- BTAI $19.84
- Technical
- Relative Strength Index (RSI)
- YCBD 51.65
- BTAI 48.12
- Support Level
- YCBD $0.90
- BTAI $1.70
- Resistance Level
- YCBD $0.99
- BTAI $2.00
- Average True Range (ATR)
- YCBD 0.06
- BTAI 0.15
- MACD
- YCBD 0.01
- BTAI -0.03
- Stochastic Oscillator
- YCBD 58.90
- BTAI 20.00
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.